In the conclusion of this Exclusive Interview, Drs. Sood and Messer talk with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about their individual diet philosophies and behavior modification.

In this week's Homerun Slides, results of the HOPE trial and LIFE Study, and the main mediators that contribute to chronic kidney disease.

Therapeutic approaches to the dyslipidemia of insulin resistance and type 2 diabetes mellitus -- Key points: The rationale for treating the diabetic dyslipidemia is clear, it is associated with significantly increased risk of cardiovascular events.Weight loss, exercise, and diet modifications are key to successful treatment of all of the lipid abnormalities in patients with T2DM. Statins are the mainstay of therapy—they lower LDL cholesterol up to 50%, lower triglycerides about 15–25%, and have minimal effects of HDL cholesterol levels.

It is kind of funny that just a little over 4 years ago the idea that the kidneys had anything to do with causing diabetes was not in the realm of medical practice. “Way back” then only the opposite was imagined: that diabetes affected the kidneys. Then Invokana was introduced …

New study finds lower occurrence of heart failure in older people with type 2.

Real-time monitoring produces significant long-term improvement in HbA1c.

Study examined effectiveness of CGM on maternal glucose control and obstetric and neonatal health outcomes.

The pendulum has swung from too much fat to too many carbs.

Even though screening the general population does not impact mortality or CVD incidence, it did have benefits for those diagnosed with diabetes.

The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) list a hierarchy of usage for antihyperglycemic medications after metformin. Which one of the following lists shows the correct hierarchy, beginning with the most preferred? A. A Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, thiazolidinediones (TZDs), basal insulins B. SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 RAs, TZDs, basal insulins C. TZDs, GLP-1 RAs, SGLT-2 inhibitors, DPP-4 inhibitors, basal insulins D. GLP-1 RAs, SGLT-2 inhibitors, basal insulins, DPP-4 inhibitors, TZDs Follow the link to see the right answer.